The possibility of preparing solid Co-crystals forms of   sulfamethoxazole-trimethoprim (SMZ-TMP)

Elbakush R. E; Albibi K

المؤلفون

Elbakush R. E Pharmaceutical Chemistry Dept Fac.of Pharmacy Misurata University Libya
Albibi K Neurosurgery department Fac of Medicine Misurata University Libya

الكلمات المفتاحية:

pharmaceutical co-crystals، solubility enhancement، antibiotic synergy، sulfamethoxazole، rimethoprim

الملخص

This study explores the preparation and characterization of solid co-crystals of sulfamethoxazole (SMZ) and trimethoprim (TMP) to enhance their pharmaceutical properties, particularly solubility and stability. SMZ-TMP co-crystals were successfully obtained using methanol, while a salt form emerged in tetrahydrofuran (THF), demonstrating solvent-dependent behavior. Various characterization techniques, including Differential Scanning Calorimetry (DSC), Fourier Transform Infrared Spectroscopy (FTIR), and Powder X-ray Diffraction (PXRD), were employed to confirm the formation and properties of the co-crystals. The SMZ-TMP co-crystal exhibited improved thermal stability and distinct molecular interactions, as evidenced by changes in FTIR hydrogen-bonding regions and thermal analysis.

المراجع

(1) Aakeröy C.B.(1997). Acta Cryst. B, 53, pp. 569-586

(2) Bettinetti G.P., Giordano, F., La Manna A., Giuseppetti G., Tadini C.(1982). Cryst. Struct. Commun., 11, pp. 821-828.

(3) Blagden N., Matas M.D., Gavan P.T., York P.(2007). Adv. Drug Deli. Rev, 59, pp. 617-630.

(4) Braga D., Grepioni F., Maini L. and Polito M.(2009). Struct. Bond., 132, pp. 25-50.

(5) Brumfitt W. (1993). Hamilton-Miller J.M. ,J. Chemother., 5(6), pp. 465–9.

(6) Byrn S. R., Pfeiffer R. R., Stowell J. G.(1999). Solid-state chemistry of drugs, 2nd Edition, SSCI, Inc., West Lafayette, Indiana.

(7) Colapietro M. J. and Portalone G.(2004). Chem. Crystallogr., 34, pp. 609-612.

(8) Deo N., Tiwari R.K. and Singh T.P.(1980). J. Sci. Res. Bhopal, India, 2, pp. 137.

(9) Egami T. and Billinge S.J.L(2003). Underneath the Bragg Peaks: Structural Analysis of Complex Materials, Pergamon, Amsterdam.

(10) Erizal Z., Yeyet C. Su. Auzal H., Lili F., Sundani N. S.(2017).Formation and Characterization of Sulfamethoxazole-Trimethoprim Cocrystal by Milling Process. Research Article | Volume: 7, Issue: 12, December.

(11) Etter M.C., Retzel S.M. and Choo C.C.(1993). J. Am. Chem. Soc., 115(10), pp. 4411-4412.

(12) Gilman A.G., Rall T.W., Nies A.S. and Taylor P.(1990). The Pharmaceutical Basis of Therabeutics, Pergamon Press, 8ht Edition, pp. 1048.

(13) Guillory J.K.(1999). In: Polymorphism in Pharmaceutical Solids, Brittain H.G. (Ed.), New York, Marcel Dekker, Inc., 1999, 5, pp. 183-226.

(14) Jones P.G.(1981). Crystal growing, chemistry in Britain, 17, pp. 222.

(15) Kagan B.M.(1974). Antimicrobial Therapy, 2nd Edition, London, W.B. SAUNDERS, COMPANY.

(16) Kemnic TR and Coleman M (2022). "Trimethoprim Sulfamethoxazole.". StatPearls Treasure Island (FL): StatPearls Publishing. PMID 30020604.

(17) Lu J. and Afr. J.(2012). Pharm. Pharmcol., 6(9), pp. 582.

(18) Lynch D. E., Smith G., Byriel K. A., Kennard C. H. L. (1991). J. Chem., 44(6), pp. 809- 819.

(19) Manius G.J.(1978). In: Analytical Profiles of Drug Substances, Florey K. (Ed.), Academic Press, INC, 1978, 7, pp. 445-475.

(20) McDonnell J.P.(1976).'In: Analytical Profiles of Drug Substances, Florey K. (Ed.), Academic Press, INC, 5, pp. 515-530.

(21) NIH,National Institutes of Health "Sulfamethoxazole" ChemDB.(2012). National Institute of Allergy and Infectious Diseases (NIAID), Archived from the original on 2012-12-15.

(22) Riviere J.E. and Papich M.G.(2009). Veterinary Pharmacology and Therapeutics, John Wiley & Sons.

(23) Roth L, Adler M, Jain T and Bempong D (2018). "Monographs for medicines on WHO's Model List of Essential Medicines". Bulletin of the World Health Organization. 96 (6): 378–385.

(24) Rudoy R.C., Nelson J.D. and Haltalin K.C.(1974).Antimicrob. Agents Chemother., 5, pp. 439-443.

(25) Rudy B.C. and Senkowski B.Z.(1973). In: Analytical Profiles of Drug Substances, Florey K. (Ed.), Academic Press, INC, 2, pp. 478.

(26) Shan N., Toda F. and Jones w.(2002). Chem. Commun., 20, pp. 2372-2373.

(27) Shekunov B.Y. and York P.(2000). J Cryst Growth, 211, pp. 122-136.

(28) Takasuka M. and Nakai H.(2001). Vib. Spec, 25, pp. 197.

(29) Tiekink E.R.T.(2006). Vittal J.J. (Ed.), Frontiers in Crystal Engineering, John Wiley & Sons, Ltd, Chapter 2: Crystal Engineering of Pharmaceutical Co-crystals, pp. 25-50.

(30) Trask A.V. and Motherwell W.D.S.(2005). Jones W., Cryst. Growth Des., 2005, 5, pp. 1013-1021.

(31) Zaini E., Sumirtapura Y.C., Soewandhi S.N.and Halim A.(2009). UEKUSA H., Fujii K., Artikel ilmiah penelitian hibah bersaing, 3(40).